other material
confidence high
sentiment positive
materiality 0.75
Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones
Actinium Pharmaceuticals, Inc.
- Upfront payment of $35 million from Immedica upon signing.
- Eligible for aggregate regulatory/commercial milestones up to ~$417 million.
- Royalties in mid-20% range on net sales in certain countries in licensed territory.
- Immedica gets exclusive rights in EUMENA; Actinium retains U.S. and rest-of-world rights.
- Actinium continues to handle clinical development and manufacturing of Iomab-B.